207 related articles for article (PubMed ID: 29061982)
1. The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.
Vilorio-Marqués L; Martín V; Diez-Tascón C; González-Sevilla MF; Fernández-Villa T; Honrado E; Davila-Batista V; Molina AJ
Sci Rep; 2017 Oct; 7(1):13806. PubMed ID: 29061982
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis.
Wang W; Wang F; Zong G; Liu R; Zhang Y; Luan Y; Xu L; Xuan J
Int J Clin Exp Med; 2015; 8(9):16043-9. PubMed ID: 26629110
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.
Wang X; Zhao H; Lv L; Bao L; Wang X; Han S
Sci Rep; 2016 Jan; 6():19239. PubMed ID: 26754405
[TBL] [Abstract][Full Text] [Related]
5. The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway.
Kurihara H; Maruyama R; Ishiguro K; Kanno S; Yamamoto I; Ishigami K; Mitsuhashi K; Igarashi H; Ito M; Tanuma T; Sukawa Y; Okita K; Hasegawa T; Imai K; Yamamoto H; Shinomura Y; Nosho K
Oncotarget; 2016 Mar; 7(11):12704-17. PubMed ID: 26871294
[TBL] [Abstract][Full Text] [Related]
6. Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells.
Böhm J; Muenzner JK; Caliskan A; Ndreshkjana B; Erlenbach-Wünsch K; Merkel S; Croner R; Rau TT; Geppert CI; Hartmann A; Roehe AV; Schneider-Stock R
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2227-2240. PubMed ID: 31317325
[TBL] [Abstract][Full Text] [Related]
7. EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.
Yamamoto I; Nosho K; Kanno S; Igarashi H; Kurihara H; Ishigami K; Ishiguro K; Mitsuhashi K; Maruyama R; Koide H; Okuda H; Hasegawa T; Sukawa Y; Okita K; Takemasa I; Yamamoto H; Shinomura Y; Nakase H
Oncotarget; 2017 Mar; 8(11):17810-17818. PubMed ID: 28147317
[TBL] [Abstract][Full Text] [Related]
8. EZH2 overexpression is associated with poor prognosis in patients with glioma.
Zhang Y; Yu X; Chen L; Zhang Z; Feng S
Oncotarget; 2017 Jan; 8(1):565-573. PubMed ID: 27880940
[TBL] [Abstract][Full Text] [Related]
9. Role of EZH2 protein expression in gastric carcinogenesis among Asians: a meta-analysis.
Guo L; Yang TF; Liang SC; Guo JX; Wang Q
Tumour Biol; 2014 Jul; 35(7):6649-56. PubMed ID: 24705718
[TBL] [Abstract][Full Text] [Related]
10. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.
Fluge Ø; Gravdal K; Carlsen E; Vonen B; Kjellevold K; Refsum S; Lilleng R; Eide TJ; Halvorsen TB; Tveit KM; Otte AP; Akslen LA; Dahl O;
Br J Cancer; 2009 Oct; 101(8):1282-9. PubMed ID: 19773751
[TBL] [Abstract][Full Text] [Related]
11. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature.
Peng L; Zhou Y; Wang Y; Mou H; Zhao Q
PLoS One; 2013; 8(3):e58891. PubMed ID: 23527044
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
14. SUMOylation of E2F1 Regulates Expression of EZH2.
Du L; Fakih MG; Rosen ST; Chen Y
Cancer Res; 2020 Oct; 80(19):4212-4223. PubMed ID: 32816857
[TBL] [Abstract][Full Text] [Related]
15. Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome: A meta-analysis.
Huang X; Wang X
Medicine (Baltimore); 2020 Aug; 99(34):e21900. PubMed ID: 32846854
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression.
Bremer SCB; Conradi LC; Mechie NC; Amanzada A; Mavropoulou E; Kitz J; Ghadimi M; Ellenrieder V; Ströbel P; Hessmann E; Gaedcke J; Bohnenberger H
Digestion; 2021; 102(2):227-235. PubMed ID: 31694013
[TBL] [Abstract][Full Text] [Related]
17. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC
Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
